CENPF (+) cancer cells promote malignant progression of early-stage TP53 mutant lung adenocarcinoma.

IF 5.9 2区 医学 Q1 ONCOLOGY
Yanlu Xiong, Jie Lei, Miaomiao Wen, Yongfu Ma, Jinbo Zhao, Yahui Tian, Zitong Wan, Xiaoyan Li, Jianfei Zhu, Wenchen Wang, Xiaohong Ji, Ying Sun, Jie Yang, Jiao Zhang, Shaowei Xin, Yang Liu, Lintao Jia, Yong Han, Tao Jiang
{"title":"CENPF (+) cancer cells promote malignant progression of early-stage TP53 mutant lung adenocarcinoma.","authors":"Yanlu Xiong, Jie Lei, Miaomiao Wen, Yongfu Ma, Jinbo Zhao, Yahui Tian, Zitong Wan, Xiaoyan Li, Jianfei Zhu, Wenchen Wang, Xiaohong Ji, Ying Sun, Jie Yang, Jiao Zhang, Shaowei Xin, Yang Liu, Lintao Jia, Yong Han, Tao Jiang","doi":"10.1038/s41389-025-00546-5","DOIUrl":null,"url":null,"abstract":"<p><p>The prevention and precise treatment of early-stage lung adenocarcinoma (LUAD) characterized by small nodules (stage IA) remains a significant challenge for clinicians, which is due largely to the limited understanding of the oncogenic mechanisms spanning from preneoplasia to invasive adenocarcinoma. Our study highlights the pivotal role of cancer cells exhibiting high expression of centromere protein F (CENPF), driven by TP53 mutations, which become increasingly prevalent during the transition from preneoplasia to invasive LUAD. Biologically, cancer cells (CENPF+) exhibited robust proliferative and stem-like capabilities, thereby propelling the malignant progression of early-stage LUAD. Clinically, autoantibodies against CENPF in the serum and elevated cancer cells (CENPF+) in tissue correlated positively with the progression of early-stage LUAD, especially those in stage IA. Our findings suggest that cancer cells (CENPF+) play a central role in orchestrating the malignant evolution of LUAD and hold potential as a novel biomarker for early-stage detection and management of the disease.</p>","PeriodicalId":19489,"journal":{"name":"Oncogenesis","volume":"14 1","pages":"5"},"PeriodicalIF":5.9000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882812/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogenesis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41389-025-00546-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The prevention and precise treatment of early-stage lung adenocarcinoma (LUAD) characterized by small nodules (stage IA) remains a significant challenge for clinicians, which is due largely to the limited understanding of the oncogenic mechanisms spanning from preneoplasia to invasive adenocarcinoma. Our study highlights the pivotal role of cancer cells exhibiting high expression of centromere protein F (CENPF), driven by TP53 mutations, which become increasingly prevalent during the transition from preneoplasia to invasive LUAD. Biologically, cancer cells (CENPF+) exhibited robust proliferative and stem-like capabilities, thereby propelling the malignant progression of early-stage LUAD. Clinically, autoantibodies against CENPF in the serum and elevated cancer cells (CENPF+) in tissue correlated positively with the progression of early-stage LUAD, especially those in stage IA. Our findings suggest that cancer cells (CENPF+) play a central role in orchestrating the malignant evolution of LUAD and hold potential as a novel biomarker for early-stage detection and management of the disease.

CENPF(+)癌细胞会促进早期 TP53 突变肺腺癌的恶性发展。
以小结节(IA期)为特征的早期肺腺癌(LUAD)的预防和精确治疗仍然是临床医生面临的一个重大挑战,这在很大程度上是由于对从瘤前病变到浸润性腺癌的致癌机制的了解有限。我们的研究强调了由TP53突变驱动的着丝粒蛋白F (CENPF)高表达的癌细胞的关键作用,这在从瘤前病变到侵袭性LUAD的转变过程中变得越来越普遍。在生物学上,癌细胞(CENPF+)表现出强大的增殖和干细胞样能力,从而推动早期LUAD的恶性进展。临床中,血清中抗CENPF自身抗体和组织中升高的癌细胞(CENPF+)与早期LUAD的进展呈正相关,尤其是IA期。我们的研究结果表明,癌细胞(CENPF+)在协调LUAD的恶性进化中起着核心作用,并具有作为早期检测和治疗该疾病的新型生物标志物的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncogenesis
Oncogenesis ONCOLOGY-
CiteScore
11.90
自引率
0.00%
发文量
70
审稿时长
26 weeks
期刊介绍: Oncogenesis is a peer-reviewed open access online journal that publishes full-length papers, reviews, and short communications exploring the molecular basis of cancer and related phenomena. It seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信